Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 338 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Comparative Effectiveness Study Clear all

Conditions: Coronary Artery Disease, Cognitive Impairment, Heart Failure
Interventions: Guideline-directed medical therapy (GDMT), Coronary artery bypass grafting (CABG), Percutaneous coronary intervention (PCI).; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 55 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: New York, New York

Conditions: Aspergillosis
Interventions: Anidulafungin, VER002; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: King of Prussia, Pennsylvania

Conditions: Urinary Tract Infections
Interventions: Gepotidacin, Placebo matching nitrofurantoin, Nitrofurantoin, Placebo matching gepotidacin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 1,606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 79
States / cities: Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 66 more

Conditions: Cutibacterium Acnes Contamination
Interventions: Irrisept Irrigation, Saline Irrigation Solution Delivery; Procedure
Lead sponsor: Orthopaedic Education and Research Institute (dba Hoag Orthopedics); Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Nocturnal Enuresis
Interventions: PureWick™ System, Hollister® Female Urinary Pouch External Collection Device; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Dunwoody, Georgia • New York, New York

Conditions: Smoker, Smoking Cessation
Interventions: Nicotine Pouches, Mini Nicotine lozenges; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Obstructive Sleep Apnea (OSA)
Interventions: Positive airway pressure (PAP) therapy, Sleep dental device, Atomoxetine-oxybutynin; Device · Drug
Lead sponsor: Sairam Parthasarathy; Other
Eligibility: 18 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 4
States / cities: Tucson, Arizona • Redwood City, California • Miami, Florida + 1 more

Conditions: Bacterial Pneumonia
Interventions: Tigecycline, Imipenem, Cilastatin; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 29
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Martinez, California + 21 more

Conditions: Procedural Bleeding, Delayed Bleeding, Post-Polypectomy Syndrome, Post Procedural Complication
Interventions: Eleview, Hetastarch; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Chronic Pain
Interventions: Medication management, Non-pharmacological pain management, Buprenorphine-Naloxone; Other · Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years and older
Enrollment: 820 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pancreatic Necrosis
Interventions: AXIOS™ stent, Double Pigtail Stents; Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Video Laryngoscopy, Quality Improvement, Operating Rooms, Comparative Effectiveness Study, Survey
Interventions: AMBU Product, CMAC-Storz, Glidescope; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
Interventions: Remigromig; Drug
Lead sponsor: EyeBiotech Ltd.; Industry
Eligibility: 50 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 27
States / cities: Phoenix, Arizona • Bakersfield, California • Modesto, California + 23 more

Conditions: Food Insecurity, Fruit and Vegetable Consumption in Children, Produce Prescription Program Utilization
Interventions: Delivered Produce Prescription, Delivered Healthy Meal Kit, Standard of Care Mobile Market Voucher; Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Scar, Keloid, Hypertrophic Scar, Cicatrix
Interventions: Placebo Cream Base Emulsion Moisturizer, FS2 Emulsion Moisturizer, Active Comparator Onion Skin Extract Gel (Mederma), Active Comparator Silicone Gel (Kelo-Cote), Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer; Other
Lead sponsor: The Center for Clinical and Cosmetic Research; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: HIV Infection
Interventions: Tenofovir DF, lopinavir/ritonavir with 2 Nucleoside RTIs; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Abbott Park, Illinois

Conditions: HRAS Gene Mutation, HNSCC
Interventions: Tipifarnib, HRAS Detection Assay; Drug · Device
Lead sponsor: Kura Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 29
States / cities: Los Angeles, California • San Francisco, California • Whittier, California + 23 more

Conditions: Hypertension, Hypertension Complicated
Interventions: RBPM, MII; Behavioral · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 16,895 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Boston, Massachusetts • Quincy, Massachusetts • Roslindale, Massachusetts

Conditions: Discogenic Low Back Pain
Interventions: Platelet-Rich Plasma (PRP) Injection, Nucleus Pulposus (NP) Injection; Biological
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 100 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
Interventions: EYE201; Drug
Lead sponsor: EyeBiotech Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 26
States / cities: Scottsdale, Arizona • Modesto, California • Mountain View, California + 21 more

Conditions: Insomnia
Interventions: Bedtime routine, Sleep schedule, Intervention (bedtime), Intervention (after night wakings); Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 6 Months to 18 Months
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Laparoscopic Cholecystectomy
Interventions: 2 capsules Oral Tylenol 2000 mg and IV "salt water", IV tylenol 1000mg and 2 oral capsule "sugar pills"; Drug
Lead sponsor: Defense and Veterans Center for Integrative Pain Management; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Fort Bragg, North Carolina

Conditions: Urinary Bladder, Overactive, Urinary Incontinence, Accidental Falls
Interventions: Pelvic Floor Muscle Training, Mirabegron, Trospium Chloride; Behavioral · Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 60 Years to 99 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
Interventions: Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide), Insulin (glargine); Drug
Lead sponsor: GRADE Study Group; Other
Eligibility: 30 Years and older
Enrollment: 7,850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 28 more

Search by objective public record fields.

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Left Ventricular Dysfunction Trial

A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).

Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)

Wound Irrigation Comparative Effectiveness Study

PureWick™ France and U.S. At-Home Pilot Study

The Options 2 Study

A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in Adults

Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia

A Comparison of Eleview Versus Hetastarch as Injectate for EMR

Veterans' Pain Care Organizational Improvement Comparative Effectiveness Study

Study of a Lumen- Apposing, Covered, Self-Expanding Metal Stent (Axios™) Versus Multiple Double Pigtail Stents

OR Video-Laryngoscope Evaluations

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

Pediatric Food is Medicine Study

"A Clinical Study Investigating the Effectiveness of OTC Scar-management Modalities"

Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

Improving Hypertension Control in Safety-Net Settings: The Boston Hypertension Equity Alliance in Treatment

PRP Versus NP Injections for Chronic Discogenic Low Back Pain

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

Infant Behavioral Sleep Intervention: Comparative Efficacy

Comparing Effectiveness of IV vs Oral Acetaminophen Given Perioperatively for Lap Choles for Pain Control,

Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes